You are here: Industry Insights > PMD-026

News List

PhoenixMD Announces First Patient Dosed in Triple Negative Breast Cancer Trial americanpharmaceuticalreview
December 11, 2020
Phoenix Molecular Designs (PhoenixMD) announced the first patient has been dosed in their Phase 1b clinical trial of PMD-026.
Phoenix Molecular Designs Receives FDA Clearance to Begin PMD-026 Trial americanpharmaceuticalreview
September 24, 2019
Phoenix Molecular Designs (PhoenixMD) received clearance from the Food and Drug Administration (FDA) for PhoenixMD's Investigational New Drug (IND) application for its proprietary PMD-026.
Phoenix Molecular, WuXi STA Reach Drug Supply Milestone contractpharma
June 10, 2019
Completes clinical trial supply to support Phase I/Ib study of PMD-026 for TNBC.
Roche, PhoenixMD collaborate on diagnostic that may help identify triple-negative breast cancer patients who might benefit from RSK inhibitor PMD-026 firstwordpharma
January 17, 2019
In September, PhoenixMD announced that it raised $2.7 million to advance PMD-026 through investigational new drug (IND)-enabling studies and to develop a companion diagnostic to determine which patients have high levels of activated RSK2.